Feature|Podcasts|October 25, 2024

Fake Weight Loss Drugs: Growing Threat to Consumer Health

In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.

UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss:

Counterfeit weight loss drugs (particularly fake Ozempic) and potential health risks
What can be done to raise awareness among consumers about the dangers of counterfeit medications
Ways increase access to legitimate weight loss medications, especially for those in underserved communities
and much more!

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Fake Weight Loss Drugs: Growing Threat to Consumer Health

Related Content

Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts

Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion

Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive

Pharmaceutical Executive Daily: Meaningfully Improving Therapy Persistence in Patient Support Programs

Trending on PharmExec

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts

FDA Pilot Targets Faster Early-Stage Drug Trial Starts

How 3D Printing Speeds Up Drug Production

The Next Evolution of Class of Trade: Why Customer Identity Is Becoming Market Access’s Hardest Problem